Drug intelligence / Profile preview

VRELysin

Development stage: Phase 2
Lead developer: Intralytix
Modality: Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

VRELysin is a bacteriophage therapy developed to target vancomycin-resistant Enterococci (VRE) colonization in the gastrointestinal tract. It is currently being evaluated in a Phase 1/2a clinical trial for its safety and efficacy in both healthy individuals and those colonized with VRE. The therapy consists of a phage cocktail designed to specifically lyse vancomycin-resistant enterococci, offering a novel approach for managing infections caused by these multidrug-resistant bacteria. The primary developer and active organization behind this drug is Intralytix.

Brand names: VRELysin
Other names: VRELysin

Beyond the preview

Go deeper on VRELysin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VRELysin.

Explore the full profile